Market Place
Sourcing Support
KEYTRUDA SC Subcutaneous Form Now Available Across UK
04 May 2026 //
FIRSTWORD PHARMA
Merck & Co.`s Keytruda posts $8B in Q1 as Qlex picks up steam
01 May 2026 //
FIRSTWORD PHARMA
Pliant Therapeutics Initiates Phase 1B Trial For PLN-101095
30 Apr 2026 //
GLOBENEWSWIRE
Merck Halts TROP ADC Development as Keytruda Clock Ticks
30 Apr 2026 //
BIOSPACE
Bioinvent International AB: Interim Report January - March 2026
29 Apr 2026 //
PHARMIWEB
Merck, Rivals Eye Inhibrx Experimental Drug Tied to Keytruda
25 Apr 2026 //
REUTERS
Hope Rises For Rare Gynaecological Clear Cell Cancer
24 Apr 2026 //
FIRSTWORD PHARMA
Labcorp Introduces Fda-Approved Ovarian Cancer Diagnostic
22 Apr 2026 //
PR NEWSWIRE
Merck’s Welireg Triplet Fails Phase 3 in first-line kidney Cancer
22 Apr 2026 //
FIERCE PHARMA
Moderna To Present Data At 2026 ASCO Conference
21 Apr 2026 //
PHARMIWEB
Bioinvent To Showcase BI-1808 And Keytruda In Ovarian Cancer
21 Apr 2026 //
PHARMIWEB
Moderna To Unveil Mrna-4359 Cancer Therapy Data At AACR 2026
17 Apr 2026 //
PHARMIWEB
Kainova Expands DT-7012 Trial to Europe and Doses First Patient
09 Apr 2026 //
PHARMIWEB
EC Approve KEYTRUDA + Paclitaxel ± Bevacizumab for Ovarian Cancer
02 Apr 2026 //
PHARMIWEB
Adagene & Incyte to Trial Muzastotug + TGFßR2xPD-1 in CRC
02 Apr 2026 //
GLOBENEWSWIRE
Ivonescimab Shows QoL Benefits in Chemo-Free NSCLC: ELCC
31 Mar 2026 //
PR NEWSWIRE
Pliant Therapeutics To Present PLN-101095 Phase 1 Trial Results
18 Mar 2026 //
GLOBENEWSWIRE
Adagene To Showcase Muzastotug (ADG126) At 2026 (AACR) Meeting
17 Mar 2026 //
GLOBENEWSWIRE
Varsetatug Masetecan Shows Promise in Late-Line Colorectal Cancer
16 Mar 2026 //
GLOBENEWSWIRE
Immutep`s Ph. 3 Failure Surprises Analysts, Sinks Stock
14 Mar 2026 //
FIERCE BIOTECH
Keytruda Hangs On To Best Seller Crown As Glp-1s Gain Ground
04 Mar 2026 //
BIOSPACE
Zydus` Keytruda Biosimilar Succeeds in FYB206 Trial
28 Feb 2026 //
INDPHARMAPOST
Keytruda + Welireg Cuts RCC Recurrence 28% VS Placebo
28 Feb 2026 //
BUSINESSWIRE
Padcev-Keytruda Combo Wins in MIBC Amid Evolving Landscape
28 Feb 2026 //
FIERCE PHARMA
PADCEV + Keytruda Cuts Recurrence, Death Risk in Bladder Cancer
27 Feb 2026 //
PHARMIWEB
Keytruda Combo Improves OS in Platinum-Resistant Ovarian Cancer
27 Feb 2026 //
BUSINESSWIRE
Synthekine, Merck Launch STK-012/Keytruda Trial for NSCLC Cancer
26 Feb 2026 //
BUSINESSWIRE
Medicenna Therapeutics Reveals Q3 Fiscal 2026 Financials
13 Feb 2026 //
GLOBENEWSWIRE
Keytruda Combo Approved for Platinum-Resistant Ovarian Cancer
12 Feb 2026 //
FDA
NMPA Approves Promega MSI Kit as KEYTRUDA Companion Diagnostic
03 Feb 2026 //
PHARMIWEB
Merck lines up $70B+ in revenue opportunities over next decade
03 Feb 2026 //
FIERCE PHARMA
FDA Accepts BLA for Ivonescimab Combo in NSCLC Post-TKI Therapy
30 Jan 2026 //
PRESS RELEASE
Kazia Shows Positive Early Results In Phase 1B Paxalisib Study
27 Jan 2026 //
PR NEWSWIRE
Blau Pharma Fully Develops Advanced Biosimilar Immunotherapy
23 Jan 2026 //
PR NEWSWIRE
Adagene Provides Business Update And 2026 Objectives
23 Jan 2026 //
GLOBENEWSWIRE
Merck, Moderna Sustain 49% Melanoma Risk Reduction At 5 Years
22 Jan 2026 //
FIERCE BIOTECH
NEJM: Ph 3 ASCENT-04/KEYNOTE-D19 Trodelvy+Keytruda Supports SoC
21 Jan 2026 //
BUSINESSWIRE
Immunomic Therapeutics Receives FDA Clearance For Unite RNA
20 Jan 2026 //
BUSINESSWIRE
ImmunityBio`s ANKTIVA Pairs with Checkpoint Inhibitors for NSCLC
13 Jan 2026 //
PHARMIWEB
Merck Confident In Growth Despite Keytruda Exclusivity Loss
13 Jan 2026 //
BIOSPACE
Merck Starts Phase 3 Trial Of Calderasib With Keytruda For NSCLC
11 Jan 2026 //
INDPHARMAPOST
Cytomx Therapeutics Unveils 2026 Business Update And Milestones
08 Jan 2026 //
GLOBENEWSWIRE
Merck Starts Phase 3 Trial of KRAS G12C Drug With Keytruda QLEX
07 Jan 2026 //
PHARMIWEB
BBOT Advances RAS And Pi3K? Pipeline With New Clinical Data
07 Jan 2026 //
GLOBENEWSWIRE
Biocon Biologics Launching Three New Cancer Biosimilars
06 Jan 2026 //
ECONOMICTIMES
Kelun Biotech Secures China`s BTD for Sac-TMT/Pembro in PD-L1+ GC
05 Jan 2026 //
PR NEWSWIRE
Bioinvent Reveals Positive Phase 2A Results For BI-1808
05 Jan 2026 //
PHARMIWEB
Pyxis Oncology Reports Positive Ph 1 Results For MICVO In Cancer
18 Dec 2025 //
GLOBENEWSWIRE
Astellas` PADCEV And Keytruda Boost Survival in Bladder Cancer
17 Dec 2025 //
PR NEWSWIRE
Inhibrx Biosciences Updates INBRX-106 And Ozekibart Expansion
16 Dec 2025 //
PR NEWSWIRE
Adagene Reveals FDA Fast Track For Muzastotug In Cancer
16 Dec 2025 //
GLOBENEWSWIRE
Medicenna Enhances MDNA11 Trial Results At ESMO-IO Congress
10 Dec 2025 //
GLOBENEWSWIRE
Medicenna Therapeutics Hosts Live Webinar On Updated MDNA11
09 Dec 2025 //
GLOBENEWSWIRE
Zydus, Formycon Partner For Exclusive Biosimilar Supply
09 Dec 2025 //
PR NEWSWIRE
Halozyme Wins German Injunction Blocking Keytruda Distribution
08 Dec 2025 //
INDPHARMAPOST
Bioinvent Unveils Positive Phase 2A BI-1808 Monotherapy Results
07 Dec 2025 //
PHARMIWEB
Bicara Phase 1b Data Supports Ficerafusp Dose for Pivotal Study
06 Dec 2025 //
GLOBENEWSWIRE
Merck`s Keytruda SC Launch In Germany Faces Legal Hurdle
05 Dec 2025 //
FIERCE PHARMA
Pliant Therapeutics: Interim PLN-101095 Data for Immune Diseases
04 Dec 2025 //
GLOBENEWSWIRE
Halozyme Secures Injunction On Merck`s Keytruda SC In Germany
04 Dec 2025 //
PR NEWSWIRE
